SPRY2 and prostate cancer: Experimental models of prostate cancer have identified PTEN and SPRY2 as important molecular determinants of aggressive prostate carcinogenesis including metastases (Ahmad et al, 2011, 2013; Schutzman & Martin, 2012; Patel et al, 2013; Assinder et al, 2015).